Time filter

Source Type

Iasi, Romania

Grigore T. Popa University of Medicine and Pharmacy is a public university-level medical school located in Iași, Romania. It was named in honor of the scientist Grigore T. Popa. Wikipedia.

Danulescu R.M.,Grigore T. Popa University of Medicine and Pharmacy
Revista medico-chirurgicalǎ̌ a Societǎ̌ţii de Medici ş̧i Naturaliş̧ti din Iaş̧i | Year: 2013

Cirrhosis is characterized by an increased susceptibility to infection. Spontaneous bacterial peritonitis (SBP) is the most common infectious complication, the main causes being the bowel bacterial overpopulation, the increased intestinal permeability and bacterial translocation. Antibiotic prophylaxis with Norfloxacin increases the rate of PBS with G+ multiresistant bacteria. To demonstrate the advantage of using rifaximin, nonresorbable broad spectrum antibiotic, in SBP prophylaxy. The study is a prospective case-control, which included 46 patients diagnosed with Child class C cirrhosis and refractory ascites, based on clinical, biological, ultrasound and endoscopic findings, followed over a period of 6 months. Protein level in ascitic fluid (AF) was higher 14 g/dl. SBP was defined as the presence of > 250 PMN/mm3. Patients were divided into 2 groups, group 1 comprised 22 patients who received rifaximin treatment during the study for a previous episode of hepatic encephalopathy (HE), and group 2 consisted of 24 patients who did not receive antibiotic treatment during follow-up. Rifaximin significantly decreases the polymorpho-nucleares (PMN) in ascitic fluid from patients, one single case of neutroascitic SBP with negative cultures were recorded in this group, with a net improvement of the general condition. In group 2 who did not follow any antibiotic treatment, SBP was recorded in 4 patients, an increase of PMN in ascitic fluid at 14 patients, an approximately constant value in 4 patients, a decrease in 2 subjects. The study suggests that rifaximin causes a significant decrease in PMN in AF, producing a decrease in SBP frequency and improvement of life in cirrhotic patients with refractory ascites. In this study, the effects of rifaximin on intestinal bacterial overpopulation and bacterial translocation, decisive factors in SBP, are consistent with literature data. Use of rifaximin as an alternative method to prevent SBP deserves more attention. Source

Antoniu S.,Grigore T. Popa University of Medicine and Pharmacy
Expert Opinion on Biological Therapy | Year: 2014

Introduction: Systemic lupus erythematosus is an autoimmune multiorgan disease in which the lack of an appropriate therapy can lead to rapid organ failure and death. Immunosuppressive therapies such as corticosteroids or cyclophosphamide can slow down the disease progression but sometimes other therapies are needed. Among such therapies, epratuzumab, an antiCD22 antibody, can be potentially efficacious in this disease. Areas covered: Discussion of the results from clinical studies evaluating the efficacy and safety of epratuzumab in patients with moderate or severe systemic lupus erythematosus. Expert opinion: The study demonstrates that epratuzumab can improve the quality of life and can reduce the disease activity burden, but the premature termination of the studies might have limited the generation of further efficacy data. © 2014 Informa UK, Ltd. Source

Antoniu S.A.,Grigore T. Popa University of Medicine and Pharmacy
Multidisciplinary Respiratory Medicine | Year: 2012

Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the existing data supporting its potential use in this disease. © 2012 Antoniu; licensee BioMed Central Ltd. Source

Antoniu S.A.,Grigore T. Popa University of Medicine and Pharmacy
Expert Opinion on Therapeutic Targets | Year: 2014

Introduction: In asthma and chronic obstructive pulmonary disease (COPD), there is an unmet therapeutic need for the anti-inflammatory therapies, and the identification of therapeutic targets and potent corresponding therapies is necessary. Although inhaled corticosteroids and leukotriene modifiers are most effective in asthma they are still not always capable of appropriately controlling the disease. In COPD, the therapeutic gap is even larger because inhaled corticosteroids and other anti-inflammatory therapies are not beneficial in all disease subsets. Areas covered: The role of the 5-lipoxygenase-activating protein (FLAP) in generating proinflammatory molecules such as leukotrienes is discussed, highlighting, in particular, its potential as a therapeutic target in asthma and COPD. The preclinical data on FLAP inhibitors are discussed. The clinical data on the FLAP inhibitors investigated so far for these diseases are analyzed. Expert opinion: FLAP inhibitors have emerged during the past decade as a promising therapeutic class in asthma and COPD, but there exists only a limited amount of data supporting their efficacy in these diseases. This might be due to the fact that the development of some of the molecules discussed was abandoned. Such therapies might be of particular interest in COPD and in asthma-COPD overlap syndrome. © 2014 Informa UK, Ltd. Source

Bild W.,Grigore T. Popa University of Medicine and Pharmacy | Ciobica A.,Al. I. Cuza University
Journal of Affective Disorders | Year: 2013

There is increasing evidence that besides the well-known angiotensin (Ang) II, other renin-angiotensin system (RAS) peptides, including Ang-(1-7), could have important effects at the central level. However, very few things are known about the central actions of Ang-(1-7), while the effects of its administration alone on anxiety have not been tested to date, to the best of our knowledge. In this way, we were interested in studying the effects of Ang-(1-7) intracerebroventricular administration on anxiety levels, as studied through some main behavioral parameters in the elevated plus maze, as well as the importance of Ang-(1-7) in the oxidative stress status from the amygdala, which is one of the key brain regions involved in mediating anxiety. We report here a possible anxiolytic-like effect of Ang-(1-7) administration, as demonstrated by the increased percentage of time spent and frequency of entries in the open arms of the elevated plus maze, as well as increased head-dipping behavior in the open arms and decreased stretching in closed arms. Also some antioxidant effects of Ang-(1-7) are suggested since a significant increase of GPX specific activity and a decrease of the main peroxidation marker MDA were observed in the amygdala. Moreover, we found a significant correlation between most of the behavioral parameters in the elevated plus maze and the levels of the oxidative stress markers. However, further studies are necessary in order to elucidate the effects of Ang-(1-7) administration on anxiety and oxidative stress status and also on the possible correlation that might exists between these aspects. © 2012 Elsevier B.V. All rights reserved. Source

Discover hidden collaborations